A total of 8,072 gram-positive isolates collected from 69 medical centers among all 9 U.S. Census Divisions during the 2015 SENTRY Antimicrobial Surveillance Program were included. Telavancin had minimal inhibitory concentration (MIC) 50 and MIC 90 values of 0.03/0.06 mg/mL, respectively, against methicillin-susceptible (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). Similar activity was also observed among coagulase-negative staphylococci (MIC 50/90 , 0.03/0.06 mg/ml; 100.0% inhibited by £0.12 mg/ml). Telavancin was active against vancomycin-susceptible Enterococcus faecalis (MIC 50/90 , 0.12/0.12 mg/ml) and Enterococcus faecium (MIC 50/90 , 0.03/0.06 mg/ml), but was less active against vancomycin-resistant E. faecium (MIC 90 , >2 mg/ml) and E. faecalis (MIC 90 , >2 mg/ml). Streptococci showed modal MIC results of 0.008 mg/ml (Streptococcus pneumoniae) to 0.015 mg/ml (b-hemolytic streptococci and viridans group streptococci). Potency variations for telavancin within Census Divisions were not observed. Telavancin remains potent in vitro against indicated pathogens recovered from U.S. medical centers (2015).
Introduction
T elavancin is a parenteral, bactericidal, semisynthetic lipoglycopeptide agent that has been shown to be noninferior to vancomycin in phase 3 clinical trials of adult patients with complicated skin and skin structure infections (cSSSI) and in hospital-acquired bacterial pneumonia (HAP), including ventilator-associated pneumonia (VAP), due to susceptible gram-positive pathogens and Staphylococcus aureus, respectively. [1] [2] [3] [4] Telavancin has been approved for clinical use by the U.S. Food and Drug Administration (FDA) in the treatment (once daily) of cSSSI and HAP/VAP and demonstrated efficacy in treating patients with either cSSSI or HAP/VAP who had concurrent S. aureus bacteremia. 4 Previous studies have demonstrated potent activity of telavancin against S. aureus, including methicillin-resistant (MRSA) strains, as well as heterogeneous vancomycinintermediate S. aureus (hVISA) and VISA isolates and vancomycin-susceptible Enterococcus faecalis. 5, 6 Not only does telavancin inhibit peptidoglycan synthesis but it also interacts with the bacterial cell membrane, causing depolarization and increased membrane permeability. 7 This dual mechanism of action contributes to the bactericidal activity of telavancin and might also prevent the emergence of resistance when it is used clinically. In fact, only one report has been published of in vivo development of a nonsusceptible phenotype while on telavancin therapy (Swartz et al., 2013) .
Recently, the broth microdilution (BMD) method recommended by the Clinical and Laboratory Standards Institute (CLSI) for testing telavancin was modified to conform to CLSI guidelines for water-insoluble agents. 6, 8, 9 The revised method includes the use of dimethyl sulfoxide (DMSO) as both the solvent and diluent of stock solutions as well as the addition of polysorbate 80 (P-80; 0.002%) to the test medium. 4, 9 The net effects of these modifications are improved solubility and decreased binding on plastic trays of the active agent with resultant improved accuracy and reproducibility of in vitro test results. 9 As might be expected, these modifications result in lower minimal inhibitory concentration values for the target pathogens requiring. The FDA, CLSI, and European Committee on Antimicrobial Susceptibility Testing (EUCAST) to reestablish quality control (QC) MIC ranges and interpretive breakpoints. 4, 6, 8, 9 Mendes et al. 6 subsequently used the revised BMD method to assess the baseline activity of telavancin against grampositive target species obtained from a limited number (N = 28 sites) of U.S. hospitals in 2011-2012. The objective of the present study was to expand on the study of Mendes et al. 6 by including isolates from a total of 69 institutions (35 states) across all 9 U.S. Census Divisions for the year 2015. Testing was performed using the revised CLSI method with the new QC MIC ranges and interpretive criteria. 8 
Materials and Methods

Organism collection
During 2015, a total of 8,072 gram-positive bacterial pathogens were collected from 69 medical centers in 35 states across all 9 U.S. Census Bureau Divisions. Each participating laboratory followed a protocol to submit consecutive isolates (1 per patient episode) determined to be pathogens to the monitoring laboratory ( JMI Laboratories, North Liberty, IA). These isolates were deemed responsible for SSSI (42.8%), pneumonia in hospitalized patients (22.5%), bloodstream infections (18.5%), urinary tract infections (5.3%), community-acquired pneumonia (4.8%), intra-abdominal infections (2.8%), and other unknown or less prevalent infections (3.1%). There were 3 to 12 medical centers in each U.S. Census Bureau Division, and a total of 631 to 1,526 strains were contributed per division. Among the 8,072 isolates tested, there were 5,123 of S. aureus (2,822 methicillin-susceptible and 2,301 MRSAs), 328 of coagulase-negative staphylococci (CoNS), 815 of Enterococcus spp., 447 of Streptococcus pneumoniae, 1,083 of b-hemolytic streptococci (BHS), and 276 of viridans group streptococci (VGS). See footnote of Table 1 for complete list of isolates included in the study. The isolates were identified locally and forwarded to the central monitoring laboratory for confirmation of species identification, using matrix-assisted laser desorption-ionization time-of-flight mass spectrometry [MALDI-TOF-MS] and/or manual methods), and reference antimicrobial susceptibility testing.
Susceptibility testing
Isolates were tested for susceptibility to telavancin and comparator agents by BMD following the CLSI-approved standard. 10 Testing was performed using panels manufactured by JMI Laboratories (North Liberty, IA). These panels provide telavancin MIC results equivalent to the revised FDAapproved BMD method. 4, 6, 8, 9 Bacterial inoculum density was monitored by colony counts to ensure an adequate number of cells for each testing event. Validation of MIC values was performed by concurrent testing of CLSI-recommended QC reference strains: S. aureus ATCC 29213, E. faecalis ATCC 29212, and S. pneumoniae ATCC 49619. 4, 8 All QC results were within published acceptable ranges. The MIC interpretations for telavancin and comparator agents, when tested against clinical isolates, were based on the most updated breakpoint criteria from CLSI (2016). The EUCAST breakpoint for teicoplanin (£2/>2 mg/ml for susceptible and resistant, respectively) was applied against BHS and VGS. 11 
Results
Activity of telavancin and comparators against S. aureus Overall, 2,822 (55.1%) of S. aureus isolates were MSSAs and 2,301 (44.9%) were MRSAs. At least 50% of S. aureus isolates from U.S. Census Divisions 2 (Mid-Atlantic, 50.0%), 6 (East South Central, 56.6%), and 7 (West South Central, 52.4%) were MRSAs, whereas <40% of isolates from divisions 1 (New England, 35.3%) and 4 (West North Central, 33.6%) exhibited that phenotype ( Table 2) .
Telavancin MIC 50/90 values (0.03/0.06 mg/ml) were identical for both MSSA and MRSA and 100.0% of isolates of S. aureus were inhibited at the approved breakpoint for susceptibility (i.e., £0.12 mg/ml) ( Tables 1 and 3 ). The activity of telavancin (MIC 50 values) against S. aureus was similar across all nine U.S. Census Divisions with MIC 90 values of 0.03-0.06 mg/ml (Table 2 ). Using CLSI breakpoints, 100.0% of isolates tested were also susceptible to daptomycin, teicoplanin, and vancomycin (Table 3) . Susceptibility rates (CLSI interpretations) to erythromycin and levofloxacin were 40.8% and 62.0%, respectively. Susceptibility percentages were much higher to ceftaroline (98.4%), gentamicin (97.2%), linezolid (>99.9%), tetracycline (95.2%), and trimethoprimsulfamethoxazole (98.4%). These agents showed comparable activity against both MSSA and MRSA (Table 3) .
Activity of telavancin against CoNS
All CoNS were inhibited by £0.12 mg/ml of telavancin ( Table 1 ). The rate of methicillin-resistant CoNS (MR-CoNS) was 55.8% overall, ranging from 24.0% in the Mountain Division to 71.4% in the West South Central Division ( Table 2 ). The activity of telavancin did not vary across the nine U.S. Census Divisions (MIC 90 , 0.06-0.12 mg/ml) ( Table 2 ). All CoNS were susceptible to daptomycin and vancomycin (Table 3) . Susceptibility percentages to linezolid and teicoplanin were also high against methicillin-susceptible CoNS (MS-CoNS) (both 100.0%) and MR-CoNS (both 98.4%). Relative to telavancin MIC 90 values, ceftaroline and daptomycin were 4-to 8-fold less potent, linezolid was 16-fold less potent, and vancomycin was 16-to 32-fold less potent against both MS-and MR-CoNS (Table 3) . Other agents tested against CoNS did not show useful (susceptibility >90%) in vitro activity, with susceptibility of £85.4% (range 41.5-85.4%) and MIC 90 values of >2 mg/ml (Table 3) .
Susceptibility to clindamycin, erythromycin, gentamicin, levofloxacin, tetracycline, and trimethoprim-sulfamethoxazole was lower for MR-CoNS than for MS-CoNS (Table 3) . For example, susceptibility to erythromycin was 24.6% for MRCoNS and 62.8% for MS-CoNS (Table 3 ). Susceptibility to levofloxacin was 35.5% for MR-CoNS and 86.2% for MSCoNS (Table 3) .
Activity of telavancin against E. faecalis
A total of 815 enterococci were tested, of which 53.7% were E. faecalis (Table 1) . These isolates were very susceptible to 
